Bio-Techne Corp
TECH
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.32B
Close$
$26.02
63.9% downside
Current Fair Value
63.9% downsideOvervalued by 63.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.32 Billion |
|---|---|
| Enterprise Value | $11.37 Billion |
| Dividend Yield | $0.32 (0.44%) |
| Earnings per Share | $0.47 |
| Beta | 1.29 |
| Outstanding Shares | 155,893,000 |
Return
| Return on Equity | 8.63% |
|---|---|
| Return on Assets | 7.03% |
| Return on Invested Capital | 10.06% |
Valuation & Multiples
| P/E Ratio | 101.82 |
|---|---|
| PEG | -24.9 |
| Price to Sales | 10.31 |
| Price to Book Ratio | 5.55 |
| Enterprise Value to Revenue | 9.36 |
| Enterprise Value to EBIT | 46.61 |
| Enterprise Value to Net Income | 62 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$0.52
Average shareholder expectationRevenue Estimate
$314.63 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.46
Average shareholder expectationRevenue Estimate
$291.75 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2170▼ 163.46% |
|---|---|
| Total Calls | 10,600▼ 98.29% |
| Total Puts | 12,900▼ 99.27% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 23.45%▼ 90.35% |
|---|---|
| Total Invested | $2.58B▼ 72.20% |
| Investors Holding | 271▼ 334.00% |
ESG Score
No data
About Bio-Techne Corp
2,100 employees
CEO: Charles Kummeth Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems , No...